Number of the records: 1  

certolizumab pegol

  1. Topical termcertolizumab pegol
    See linkCDP 870 (UF)
    CDP870 (UF)
    certolizumab pegovaný (UF)
    Cimzia (UF)
    kertolizumab pegol (UF)
    See alsohumanizované monoklonální protilátky
    imunoglobuliny - Fab fragmenty
    polyethylenglykoly
    TNF-alfa (RT)
    antirevmatika (PA)
    imunosupresiva (PA)
    inhibitory TNF (PA)
    Linking entryCertolizumab Pegol
    ConspectD05. - 750. - 741. - 125
    D12. - 644. - 541. - 500. - 650. - 250
    D12. - 776. - 124. - 486. - 485. - 114. - 224. - 060. - 500
    D12. - 776. - 124. - 486. - 485. - 680. - 650. - 250
    D12. - 776. - 124. - 790. - 651. - 114. - 224. - 060. - 500
    D12. - 776. - 124. - 790. - 651. - 680. - 650. - 250
    D12. - 776. - 377. - 715. - 548. - 114. - 224. - 200. - 500
    D12. - 776. - 377. - 715. - 548. - 680. - 650. - 250
    NoteA polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
    DatabaseMESH
    References (4) - MESH
    subject heading

    subject heading

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.

Accept allSettingsReject all